At this stage, the p1a/b will only be investigating CPACS in Anthracyclines (3/18 drugs in the earlier table).
@Brucekoala They can't talk about it because it's an extension of the collaboration work on Zan that has not yet been published. The significance of this paper will only be truly understood in hindsight IMO.
Watch for the ICO Society conference where Dent advises clinicians (globally) that almost half of all chemotherapeutics significantly reduce HCM viability - and they've found a drug that might mitigate this...
Cardioprotection thread, page-237
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.000(0.00%) |
Mkt cap ! $291.7M | |||
| Open | High | Low | Value | Volume |
| $1.79 | $1.79 | $1.70 | $230.8K | 133.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 20397 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 7 | 1 |
View Market Depth
| Last trade - 13.32pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.77 |
Change
0.000 ( 0.39 %) |
||||
| Open | High | Low | Volume | ||
| $1.76 | $1.77 | $1.70 | 12362 | ||
| Last updated 13.35pm 07/06/2024 ? | |||||
| RAC (ASX) Chart |